Get the Stockscreener App
878.24
2.09%
-18.76
After Hours:
875.00
-3.24
-0.37%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $878.24, with a volume of 2.74M.
It is down -2.09% in the last 24 hours and down -16.52% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$897.00
Open:
$896
24h Volume:
2.74M
Relative Volume:
0.91
Market Cap:
$784.58B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
38.88
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-3.14%
1M Performance:
-16.52%
6M Performance:
+21.21%
1Y Performance:
+6.88%
1-Day Range:
$877.11
$900.83
1-Week Range:
$877.11
$926.77
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
878.24 | 784.58B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.45 | 579.15B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
209.40 | 370.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.63 | 295.77B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
188.42 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Lilly’s Taltz plus Zepbound shows efficacy in psoriatic arthritis trial - Investing.com
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity - Eli Lilly
1 Reason Eli Lilly Stock Is Still a Buy - The Motley Fool
Czech National Bank Boosts Holdings in Eli Lilly and Company - National Today
Eli Lilly Defends GLP‑1 Franchise As EBGLYSS Data Support Diversification - simplywall.st
Eli Lilly Keeps Most Of Weight Loss Drug Copy Suit Alive - Law360
Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly - FinancialContent
Eli Lilly targets Civil War-era whistleblower law at US Supreme Court - Reuters
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch
Eli Lilly Stock (LLY) Gets a Boost From Latest Trial Results. It Has Nothing to Do with Obesity Drugs - TipRanks
RICO suit vs. Lilly could reap billions if successful - The Indiana Lawyer
MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation - Stocktwits
Judge Advances Lilly Suit Over Online Platforms’ Mounjaro Copies - Bloomberg Law News
Eli Lilly stock price forecast: bears dominate as LLY consolidates near 200-day support - Traders Union
Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy? - The Motley Fool
Clark Foundation, Lilly to partner on new downtown basketball court - Indiana Economic Digest
Morgan Stanley reiterates Overweight on Eli Lilly stock, $1,313 target By Investing.com - Investing.com India
Morgan Stanley reiterates Overweight on Eli Lilly stock, $1,313 target - Investing.com
Jefferies reiterates Buy on Eli Lilly stock, $1,300 target - Investing.com
Lilly’s Ebglyss shows four-year efficacy in eczema study - Investing.com
Erste Group Bank Raises Eli Lilly's FY2027 Earnings Forecast - National Today
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis - PR Newswire
AI Models Split on Eli Lilly: Strong Fundamentals, Premium Valuation - TipRanks
Pensionfund Sabic Buys $1.83M Stake in Eli Lilly - National Today
Pensionfund Sabic Makes New Investment in Eli Lilly and Company - National Today
Institutional Investors Are Selling One of Wall Street's Premier Trillion-Dollar Club Members (No, Not Nvidia!) - The Motley Fool
Bath Savings Trust Co Boosts Stake in Eli Lilly - National Today
MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN
Vanguard disaggregation: Eli Lilly (NYSE: LLY) ownership shows 0 shares - Stock Titan
Eli Lilly & Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Eli Lilly & Co. stock underperforms Thursday when compared to competitors - MarketWatch
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Why is Eli Lilly stock down today? - Traders Union
The Bull Case For Eli Lilly (LLY) Could Change Following Retatrutide Milestone And Governance ShiftLearn Why - simplywall.st
Eli Lilly stock price forecast: consolidation after recovery as LLY holds above long-term support - Traders Union
Eli Lilly's Sustainability in Pharmaceuticals Strategy - Sustainability Magazine
Avanza Fonder AB Has $33.82 Million Position in Eli Lilly and Company $LLY - MarketBeat
Assenagon Asset Management S.A. Decreases Stock Position in Eli Lilly and Company $LLY - MarketBeat
Sen. Angus S. King Jr. Sells Off Shares of Eli Lilly and Company (NYSE:LLY) - MarketBeat
Eli Lilly & Co. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Buy Eli Lilly Stock (LLY) as Employers Move to Cover Obesity Drugs, Says Morgan Stanley - TipRanks
Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer? - Insider Monkey
Assessing Eli Lilly (LLY) Valuation After The Recent Share Price Pullback - simplywall.st
Eli Lilly and the ‘societal obligation’ of GLP-1s - statnews.com
AI Models Split on Eli Lilly: Strong Growth vs. Premium Valuation - TipRanks
Spartan Planning & Wealth Management Buys Shares of 1,556 Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Purchased by Dynamic Advisor Solutions LLC - MarketBeat
Biocon To Benefit After Eli Lilly Joins Novo Nordisk To Exit European Insulins Market - NDTV Profit
INNOVENT BIO-Eli Lilly Strategic Collaboration Deal Takes Effect; Rumored Acquisition Intent Not True - AASTOCKS.com
Eli Lilly to phase out select insulin products across Europe by 2027 - MSN
Workforce was region’s secret weapon in winning Eli Lilly | Opinion - PennLive.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):